Introduction {#s1}
============

Several strategies exist for the pursuit of drugs to treat neglected tropical diseases. Major approaches can generally be classified as: (A) **label extension**, extending the indications of existing drugs for other conditions to tropical diseases; (B) **piggy-back discovery**, in which the discovery of new drugs is focused on one or a few classes of well-studied and validated targets; and (C) **de novo drug discovery** [@pntd.0000804-Nwaka1]. These strategies collectively seek to exploit two possible sets of drug targets: those that have been validated in other organisms and diseases, and those that have not -- perhaps because they are unique to neglected-disease pathogens -- but that nevertheless have potential as novel sites of action.

Since experimental investigations of possible drug targets are time-consuming and expensive, it is worthwhile to conduct *in silico* analyses [@pntd.0000804-Anishetty1]--[@pntd.0000804-Raman1] to identify the proteins most worthy of experimental follow-up. These analyses consider traits commonly thought to be desirable in a drug target, including essentiality, druggability (whether drug-like molecules are likely to interact with the target), assayability, specificity/selectivity (potential for inhibiting the pathogen without harming the host), and importance in life-cycle stages of the pathogen relevant to human health. Inferring these traits from experimental data is a nontrivial task. For example, guesses at a target\'s essentiality can be made from gene knockout experiments with the pathogen of interest [@pntd.0000804-Murry1] or related organisms [@pntd.0000804-Caffrey1], [@pntd.0000804-Kumar1], from naturally occurring gene deletions in clinical isolates [@pntd.0000804-Tsolaki1], from microarray and/or proteomic data [@pntd.0000804-Tarun1], and/or from metabolic chokepoint (flux balance) studies [@pntd.0000804-Yeh1], [@pntd.0000804-Chavali1]. Since the best choices are partly a matter of opinion, there is a clear need for databases that are flexible enough to integrate datasets from different sources and to filter these datasets based on the preferences of individual researchers.

To facilitate target-focused analyses for pathogens prioritized by the World Health Organization\'s Special Programme for Research and Training in Tropical Diseases (TDR), TDRtargets.org [@pntd.0000804-Aguero1] was created as a central repository of target-related data. The database may be used for two general scientific tasks: (A) analysis of individual proteins, finding information that relates to their potential as drug targets; and (B) genome-level analysis, sorting and ranking multiple proteins as drug target candidates according to user-specified criteria. The latter task is the main focus of this paper.

TDRtargets.org is designed to facilitate multiple approaches to target prioritization. Users can browse target lists that others have posted (<http://tdrtargets.org/published>), generate their own lists from standard criteria offered by the database, and/or extend the criteria used to rank prospective targets by uploading files representing additional published or unpublished data. A previous publication [@pntd.0000804-Aguero1] has outlined the user interface and concepts underlying the possible queries. In this study, we provide examples of whole-genome prioritization of targets, focusing on key issues for the specific diseases covered. We use these prioritization tools to generate lists of promising drug targets for TDR organisms -- lists which provide useful starting points for target characterization in these organisms, as well as illustrate the general utility and versatility of TDRtargets.org in identifying and ranking targets.

Materials and Methods {#s2}
=====================

Database Infrastructure {#s2a}
-----------------------

We have previously described the construction of the TDRtargets.org database, as well as the formulation of searches (queries) to identify proteins meeting criteria of interest and the viewing, saving, and exporting of search results [@pntd.0000804-Aguero1]. Since then, while the overall workflow of the database has remained the same, additional genomes and datasets have been included (see below), and several improvements have been implemented on the user interface side of the database. Although users have always been able to perform "weighted union" queries, with different weights (point values) assigned to different user-specified criteria, formulating these queries and viewing and adjusting their results has recently been made more convenient. To construct a weighted union query from the website\'s target search page, a user (1) selects a pathogen (e.g., *P. falciparum*), (2) selects a criterion (e.g., functional category  =  enzyme) with which to query the pathogen genes, (3) enters a name and a weight for the query in the "Run this query" sub-menu at the bottom of the page, (4) clicks the "Next Query" button, and (5) repeats steps 2 to 4 until the last criterion is entered, at which point the user selects "Run this query" rather than "Next Query." The search results are displayed on a page where users have the option of changing the previously entered weights for each criterion ([Figure 1](#pntd-0000804-g001){ref-type="fig"}). (These results are archived on the user\'s history page, where he/she can combine different subsets of previous queries with the Union function to obtain new ranked target lists.) The presentation of ranked lists has also been revised to display the criteria met by each protein ([Figure 1](#pntd-0000804-g001){ref-type="fig"}). Further flexibility in data analysis is provided by an option to export the results to a dynamic spreadsheet so that proteins\' fulfillment of individual criteria can be viewed and the weights of the criteria can be adjusted offline.

![Highlights of the new, improved display of query results in TDRtargets.org.\
(A) The "Your scoring strategy" panel displays and allows adjustment of weights associated with each criterion. (B) An additional panel shows the distribution of weights among the proteins in the genome. To generate this histogram, all weights in the prioritization strategy were divided into 10 bins; the mean weight for each bin is shown below the x axis. In this example, most proteins had a weight of 0--100, with a small number exceeding 300. (C) Proteins are displayed in descending order of total weight; a grid shows the criteria that were met by each protein.](pntd.0000804.g001){#pntd-0000804-g001}

Using External Data in TDRtargets.org {#s2b}
-------------------------------------

The TDRtargets.org web application lets users take advantage of datasets obtained externally or in-house. Lists of genes matching user-defined criteria may be saved as text files (each containing a column of gene identifiers -- one per line -- plus an optional second column for point values, if the targets have been ranked outside of TDRtargets.org) and uploaded at the user\'s history page. Uploaded lists can be combined with other gene sets from the same organism using any of the history page tools, including ranking by weighted union.

In the present work, a number of target lists meeting different criteria were obtained from external resources, uploaded into TDRtargets.org, and used in various prioritization strategies (see [Results](#s3){ref-type="sec"}), as follows. (A) *T. cruzi* genes with proteomic evidence of expression in amastigotes (at least 2 mass spectra/peptides mapped to the protein) were obtained from TriTrypDB.org [@pntd.0000804-Aslett1]. (B) *S. mansoni* genes with evidence for expression at the transcript level (i.e., genes with mapped expressed sequence tags derived from the "egg," "schistosomula," and "adult worm" cDNA libraries) were taken from SchistoDB.net [@pntd.0000804-Zerlotini1]. (C) *Drosophila melanogaster* genes associated with abnormal phenotype tags (i.e., "lethal" and "neurophysiological defect") were taken from FlyBase.org [@pntd.0000804-Tweedie1]. This list was converted into a list of the corresponding *S. mansoni* orthologs (available from OrthoMCL.org [@pntd.0000804-Aslett1]) before uploading into TDRtargets.org.

Genome Data and Functional Datasets {#s2c}
-----------------------------------

The current version of the database includes genome data for ten different pathogens (*Brugia malayi, Leishmania major*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Plasmodium falciparum*, *Plasmodium vivax*, *Schistosoma mansoni, Toxoplasma gondii*, *Trypanosoma brucei*, and *Trypanosoma cruzi*) and one endosymbiont bacterium (*Wolbachia,* endosymbiont of *B. malayi*). The depth of data coverage in various functional datasets (searchable at <http://tdrtargets.org/search>) varies for different organisms; wherever possible, gaps in coverage are compensated for by mapping relevant information from orthologous proteins in other organisms. (For example, protein structure data available for *P. falciparum* proteins were mapped to *P. vivax* proteins.) Ortholog identification on whole genomes was carried out using tools available from OrthoMCL.org [@pntd.0000804-Chen1]. Data recently added to TDRtargets.org include curated data on production of recombinant proteins and activity assays from BRENDA [@pntd.0000804-Chang1]; three-dimensional models of proteins from *B. malayi* and its endosymbiont *Wolbachia*, *M. leprae*, and *S. mansoni,* obtained from ModBase [@pntd.0000804-Pieper1]; and phylogenetic information on *Arabidopsis thaliana* (so that users can search for proteins with or without orthologs in plants).

Ranking Target Genes via Weighted Unions {#s2d}
----------------------------------------

TDRtargets.org has a flexible ranking system for prioritizing target proteins. In multi-criteria searches, it is possible to take a Boolean intersection of the criteria so that only those proteins with all of the desired traits (e.g., essentiality AND druggability AND assayability, etc.) are selected. However, a protein may lack one or more preferred properties and still be the target of an effective drug ([Table 1](#pntd-0000804-t001){ref-type="table"}). Therefore the prioritization queries presented below are devised as weighted unions (see "Database infrastructure" above), in which each criterion is assigned a subjective weight (point value) and targets earn points for each criterion they meet. (Less important and undesirable criteria are given small and negative weights, respectively.) These queries return ranked lists of all potential targets, ordered by cumulative score. Target lists can then be re-ranked, if desired, by changing the weights and/or adding additional criteria (see "Database infrastructure" above).

10.1371/journal.pntd.0000804.t001

###### Primary targets of drugs used clinically against TDR-prioritized pathogens.

![](pntd.0000804.t001){#pntd-0000804-t001-1}

  Target                                         Gene ID          Pathogen                        Drug                   Molecularweight (kDa)   Trans-membrane domains   PDB structures   ModBase models   Ortholog in humans   Drug-gability   Compound Desirability   Assay-ability
  ------------------------------------------- -------------- ------------------- -------------------------------------- ----------------------- ------------------------ ---------------- ---------------- -------------------- --------------- ----------------------- ---------------
  Cytochrome b                                    *cytb*       *P. falciparum*                 Atovaquone                         43                       8                    N                N                  Y                                                          N
  Cytochrome P-450 14α-demethylase             LmjF11.1100       *L. major*                   Fluconazole                         54                       0                    N                Y                  Y                 0.8                0.43                  N
  Dihydrofolate reductase                        PFD0830w      *P. falciparum*    Pyrimethamine, Cycloguanil/Proguanil            72                       0                    Y                Y                  Y                  1                 0.56                  Y
  Dihydrofolate reductase                       50.m00016        *T. gondii*                 Pyrimethamine                        69                       0                    N                N                  Y                 0.8                0.56                  Y
  Dihydropteroate Synthase                        ML0224         *M. leprae*                    Dapsone                           29                       ND                   Y                Y                  N                                                          Y
  Dihydropteroate Synthase                      PF08_0095      *P. falciparum*                Sulfadoxine                         83                       0                    N                Y                  N                 0.8                                      Y
  Dihydropteroate Synthase                      55.m00011        *T. gondii*                  Sulfadiazine                        83                       0                    N                N                  N                 0.8                                      N
  InhA (NADH-dependent enoyl ACP reductase)       Rv1484      *M. tuberculosis*                Isoniazid                          29                       0                    Y                Y                  N                 0.7                0.64                  Y
  Ornithine decarboxylase                      Tb11.01.5300      *T. brucei*              Eflornithine (DMFO)                     49                       0                    Y                Y                  Y                  1                 0.43                  Y
  RNA Polymerase                                  ML1891         *M. leprae*                   Rifampicin                         130                      ND                   N                Y                  Y                                    0.29                  Y
  RNA Polymerase                                 Rv00667      *M. tuberculosis*                Rifampicin                         129                      0                    N                N                  Y                 0.7                0.29                  Y

In general, the following might be considered desirable target traits: a low molecular weight and a lack of transmembrane (TM) domains (to favor expression and solubility of recombinant protein), existence of 3D crystal structures and ModBase models (for structure-based drug design), absence of orthologs from humans (to favor selectivity), high druggability and compound desirability scores (0-to-1 scale), and a precedent for assayability. Abbreviations: PDB, Protein Data Bank; Y, yes; N, no; ND, not determined. Note that each target has some desirable features, but few are "perfect."

Overview of Queries Presented in This Paper {#s2e}
-------------------------------------------

The criteria used in generating the lists presented below are summarized in [Figure 2](#pntd-0000804-g002){ref-type="fig"}. As a starting point, a basic set of criteria of general interest were chosen to frame a "standard" query for identifying targets in *L. major* (see Query 2 in [Figure 2](#pntd-0000804-g002){ref-type="fig"}). In compiling this basic set of criteria, we included most datasets that are commonly available for organisms with complete genomic information so that the standard query could be easily applied to different pathogens. Queries 3, 4, and 5 of [Figure 2](#pntd-0000804-g002){ref-type="fig"} are examples of extending the standard query. Queries 6, 7, 8, and 9 of [Figure 2](#pntd-0000804-g002){ref-type="fig"} are framed in a pathogen-specific manner to prioritize target proteins from a particular metabolic pathway, subcellular location, or life-cycle stage. These queries make use of criteria based on external datasets uploaded to TDRtargets.org. (Readers can explore the upload tool at <http://tdrtargets.org/history>.) Queries 10 and 11 of [Figure 2](#pntd-0000804-g002){ref-type="fig"} were based heavily on data obtained by manual curation of the literature [@pntd.0000804-Berriman1] and homology/orthology analysis for protein-specific information, illustrating how even incompletely annotated genomes are amenable to target identification. Additional details of these queries are noted below.

![A summary of the multiparameter search queries presented in this study.\
Ten different queries (Queries 2--11) are listed as individual columns for which the criteria are shown on the left. For each criterion, the number of qualifying proteins from a given pathogen is shown in black and the associated weight is shown in red within parentheses. Symbols: (\#) enzymes were selected by combining searches by EC number and by functional category, except for Queries 10 and 11, which were based only on EC number; (&) the conserved-in-taxon criterion refers to the presence of orthologs in *L. major*, *T. brucei*, and *T. cruzi* ([Tables 2](#pntd-0000804-t002){ref-type="table"} and [3](#pntd-0000804-t003){ref-type="table"}), *P. falciparum* and *P. vivax* ([Tables 4](#pntd-0000804-t004){ref-type="table"} and [7](#pntd-0000804-t007){ref-type="table"}), *M. tuberculosis* and *M. leprae* ([Table 5](#pntd-0000804-t005){ref-type="table"}), and *L. major* and *T. cruzi* ([Table 8](#pntd-0000804-t008){ref-type="table"}); (¶) druggability and compound desirability scores were queried using respective cutoff values of ≥0.6 and \>0.3 ([Tables 2](#pntd-0000804-t002){ref-type="table"} to [](#pntd-0000804-t003){ref-type="table"} [](#pntd-0000804-t004){ref-type="table"} [5](#pntd-0000804-t005){ref-type="table"}), ≥0.4 and \>0.2 ([Tables 6](#pntd-0000804-t006){ref-type="table"} and [7](#pntd-0000804-t007){ref-type="table"}), and ≥0.5 (druggability scores only; [Table 8](#pntd-0000804-t008){ref-type="table"}).](pntd.0000804.g002){#pntd-0000804-g002}

Results {#s3}
=======

Searching for Candidate Drug Targets in *Leishmania* {#s3a}
----------------------------------------------------

An example of the weighted-union approach to target prioritization (see [Methods](#s2){ref-type="sec"}) is shown in Query 2 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}, which covers the *Leishmania major* genome. In this example, points are awarded for many of the criteria covered in [Table 1](#pntd-0000804-t001){ref-type="table"}, plus some additional conditions. From these criteria a list of prioritized targets is generated ([Table 2](#pntd-0000804-t002){ref-type="table"}). Such a list is hardly the final word in *Leishmania* target selection, however. The researchers who generated the list in [Table 2](#pntd-0000804-t002){ref-type="table"} may subsequently decide that, since essentiality data for *Leishmania* genes are very limited, they will consider the presence of an essential ortholog in at least one other organism to be an acceptable predictor of essentiality. Orthologous proteins usually have the same function [@pntd.0000804-Chen2], and several studies indicate that having essential orthologs is predictive of essentiality [@pntd.0000804-Sakharkar1], [@pntd.0000804-Doyle1]. The researchers could then amend their initial query so that, for example, 50 additional points are awarded to targets whose orthologs are essential in *C. elegans*, *E. coli*, *M. tuberculosis*, and/or *S. cerevisiae* (the four organisms for which genome-wide essentiality data are available in TDRtargets.org). Such a revision can easily be made by running a new query using the "Any evidence of essentiality in any species" option within the Essentiality subsection of the Search For Genes/Targets page and then using the query history page to find the union of this query and the previous one. The results are similar to but distinct from the previous results ([Table 3](#pntd-0000804-t003){ref-type="table"}).

10.1371/journal.pntd.0000804.t002

###### Preliminary genome-wide prioritization of *Leishmania major* targets.

![](pntd.0000804.t002){#pntd-0000804-t002-2}

  Ranking     Gene_name                                         Gene product                                         Weight
  --------- ------------- ----------------------------------------------------------------------------------------- --------
  1          LmjF29.0820   cysteine peptidase C (CPC),CPC cysteine peptidase, Clan CA, family C1, Cathepsin B-like    416
  2          LmjF05.0350                                   trypanothione reductase                                    386
  2          LmjF06.0860                        dihydrofolate reductase-thymidylate synthase                          386
  2          LmjF23.0050             cyclophilin, putative,peptidyl-prolyl cis-trans isomerase, putative              386
  2          LmjF25.0910                                        cyclophilin a                                         386
  2          LmjF06.0120                                         cyclophilin                                          386
  2          LmjF18.0270                 protein kinase, putative,glycogen synthase kinase, putative                  386
  8          LmjF36.1960                                phosphomannomutase, putative                                  366
  8          LmjF23.0270                                    pteridine reductase 1                                     366
  10         LmjF30.2970                    glyceraldehyde 3-phosphate dehydrogenase, glycosomal                      351
  10         LmjF12.0220             hydroxyacylglutathione hydrolase, putative,glyoxalase II, putative               351
  10         LmjF24.0850                                  triosephosphate isomerase                                   351
  13         LmjF27.1870                             trypanothione synthetase, putative                               341
  13         LmjF06.0560                  deoxyuridine triphosphatase, putative,dUTP diphosphatase                    341
  15         LmjF21.0250                                    hexokinase, putative                                      336
  15         LmjF25.1320                       serine/threonine protein phosphatase, putative                         336
  15         LmjF19.0550         methionine aminopeptidase, putative,metallo-peptidase, Clan MG, Family M24           336
  15         LmjF34.1260                     mitochondrial DNA polymerase I protein A, putative                       336
  15         LmjF30.0880                                 adenosine kinase, putative                                   336
  15         LmjF33.1630                                    cyclophilin, putative                                     336
  15         LmjF10.0890                   FKBP-type peptidyl-prolyl cis-trans isomerase, putative                    336
  15         LmjF04.1160                      fructose-1,6-bisphosphatase, cytosolic, putative                        336
  15         LmjF23.0950           cytosolic leucyl aminopeptidase,metallo-peptidase, Clan MF, Family M17             336
  15         LmjF32.1580                             phosphomannose isomerase, putative                               336
  25         LmjF36.2380                           sterol 24-c-methyltransferase, putative                            326
  25         LmjF36.2390                           sterol 24-c-methyltransferase, putative                            326

Top targets according to the criteria shown in Query 2 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}. Complete genome-wide rankings for this example and all other examples discussed in the paper ([Tables 3](#pntd-0000804-t003){ref-type="table"}--[](#pntd-0000804-t004){ref-type="table"} [](#pntd-0000804-t005){ref-type="table"} [](#pntd-0000804-t006){ref-type="table"} [](#pntd-0000804-t007){ref-type="table"} [](#pntd-0000804-t008){ref-type="table"} [](#pntd-0000804-t009){ref-type="table"} [](#pntd-0000804-t010){ref-type="table"} [11](#pntd-0000804-t011){ref-type="table"}) are available online at <http://www.tdrtargets.org/published/browse/366>. Please note that multiple targets often receive the same total weight, and that the order in which these "tied" targets are displayed has no significance.

10.1371/journal.pntd.0000804.t003

###### Revised *L. major* rankings after incorporating an essential-in-other-species criterion.

![](pntd.0000804.t003){#pntd-0000804-t003-3}

  Ranking      Gene name                                          Gene product                                         Weight
  --------- --------------- ----------------------------------------------------------------------------------------- --------
  1           LmjF29.0820    cysteine peptidase C (CPC),CPC cysteine peptidase, Clan CA, family C1, Cathepsin B-like    466
  2           LmjF05.0350                                    trypanothione reductase                                    436
  2           LmjF06.0860                         dihydrofolate reductase-thymidylate synthase                          436
  2           LmjF23.0050              cyclophilin, putative,peptidyl-prolyl cis-trans isomerase, putative              436
  2           LmjF25.0910                                         cyclophilin a                                         436
  2           LmjF06.0120                                          cyclophilin                                          436
  2           LmjF18.0270                  protein kinase, putative,glycogen synthase kinase, putative                  436
  8           LmjF36.1960                                 phosphomannomutase, putative                                  416
  9           LmjF30.2970                     glyceraldehyde 3-phosphate dehydrogenase, glycosomal                      401
  9           LmjF24.0850                                   triosephosphate isomerase                                   401
  11          LmjF21.0250                                     hexokinase, putative                                      386
  11          LmjF25.1320                        serine/threonine protein phosphatase, putative                         386
  11          LmjF19.0550          methionine aminopeptidase, putative,metallo-peptidase, Clan MG, Family M24           386
  11          LmjF34.1260                      mitochondrial DNA polymerase I protein A, putative                       386
  11          LmjF30.0880                                  adenosine kinase, putative                                   386
  11          LmjF33.1630                                     cyclophilin, putative                                     386
  11          LmjF32.1580                              phosphomannose isomerase, putative                               386
  18          LmjF35.0030                                   pyruvate kinase, putative                                   366
  18          LmjF36.1260                              fructose-1,6-bisphosphate aldolase                               366
  *18*       *LmjF35.0020*                                 *pyruvate kinase, putative*                                 *366*
  *18*       *LmjF16.1540*                    *DNA polymerase I alpha catalytic subunit, putative*                     *366*
  *18*       *LmjF20.0100*                           *phosphoglycerate kinase C, glycosomal*                           *366*
  *18*       *LmjF18.0990*                  *UTP-glucose-1-phosphate uridylyltransferase 2, putative*                  *366*
  *18*       *LmjF18.0090*                          *alpha glucosidase II subunit, putative*                           *366*
  *18*       *LmjF21.1080*                    *cell division protein kinase 2,cdc2-related kinase*                     *366*
  *18*       *LmjF26.0140*                             *adenine phosphoribosyltransferase*                             *366*
  *18*       *LmjF12.0530*                               *glucose-6-phosphate isomerase*                               *366*
  18          LmjF23.0270                                     pteridine reductase 1                                     366
  *18*       *LmjF33.1690*                     *DNA polymerase delta catalytic subunit, putative*                      *366*
  *18*       *LmjF28.2280*                                   *DNA topoisomerase ii*                                    *366*

Top targets according to the criteria shown in Query 3 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}. Italicized targets are those that were not top-ranked in the list shown in [Table 2](#pntd-0000804-t002){ref-type="table"}.

Now consider a more drastic revision of the *Leishmania* search: application of the previous criteria ([Figure 2](#pntd-0000804-g002){ref-type="fig"}, Query 3) to two other pathogens, namely *P. falciparum* and *M. tuberculosis*. This too is readily done within TDRtargets.org -- there is a "Change species" option on the Query History page -- again highlighting the ease of modifying previous searches. While use of exactly the same criteria to prioritize targets in different species might seem naïve, the results ([Tables 4](#pntd-0000804-t004){ref-type="table"} and [5](#pntd-0000804-t005){ref-type="table"}) are instructive. First of all, the top-ranked proteins of each species are rather different, showing that this search strategy is sensitive to species differences, as opposed to being unalterably biased toward the same proteins in every species. Second, many of the top-ranked targets in each species appear to be appealing options. For example, the three top-scoring targets from each species -- dihydrofolate reductase/thymidylate synthase, enoyl-ACP reductase, and triose-phosphate isomerase in *P. falciparum* and enoyl-ACP reductase (InhA), glutamine synthetase, and 5-enolpyruvylshikimate-3-phosphate synthase (AroA) in *M. tuberculosis* -- have all attracted interest as proven or prospective targets [@pntd.0000804-Adane1]--[@pntd.0000804-Oliveira1]. It is interesting that legitimate candidates such as these rise to the top of the target rankings despite certain quirks of this "one set of criteria fits all species" example. In the *M. tuberculosis* prioritization, for instance, many of the top-ranked targets are essential even though the genome-wide mutagenesis data available for this species were not queried. Thus, although these lists are imperfect, they generally suggest that rational choices of criteria lead to plausible and informative rankings of target desirability across species.

10.1371/journal.pntd.0000804.t004

###### Application of standard search criteria to *P. falciparum*.
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  Ranking     Gene name                               Gene product                               Weight
  --------- ------------- --------------------------------------------------------------------- --------
  *1*        *PFD0830w*        *bifunctional dihydrofolate reductase-thymidylate synthase*       *486*
  *2*        *PFF0730c*                      *enoyl-acyl carrier reductase*                      *461*
  *3*        *PF14_0378*                      *triose-phosphate isomerase*                       *451*
  4           PF11_0282        deoxyuridine 5′-triphosphate nucleotidohydrolase, putative         436
  4           PFC0975c          PFCYP19, cyclophilin, peptidyl-prolyl cis-trans isomerase         436
  4           PF10_0289                       adenosine deaminase, putative                       436
  4           PFI1105w                           Phosphoglycerate kinase                          436
  4           PF14_0192                           glutathione reductase                           436
  4           PFE1050w         adenosylhomocysteinase(S-adenosyl-L-homocysteine hydrolase)        436
  10          PFD0980w               holo-(acyl-carrier protein) synthase, putative               426
  10          PFF1105c                             chorismate synthase                            426
  12          PFF0160c            dihydroorotate dehydrogenase, mitochondrial precursor           416
  12          PF14_0053                  ribonucleotide reductase small subunit                   416
  12          PF14_0425                      fructose-bisphosphate aldolase                       416
  15          PF14_0641              1-deoxy-D-xylulose 5-phosphate reductoisomerase              411
  15          PFB0505c     beta-ketoacyl-acyl carrier protein synthase III precursor, putative    411
  17          PF14_0164                   NADP-specific glutamate dehydrogenase                   401
  17          PF14_0142              serine/threonine protein phosphatase, putative               401
  17          PF11_0377                              casein kinase 1                              401
  17          PFL2275c                  70 kDa peptidylprolyl isomerase, putative                 401
  17          PF13_0287                        adenylosuccinate synthetase                        401
  17          PF10_0121                  hypoxanthine phosphoribosyltransferase                   401
  23          PF08_0095                        dihydropteroate synthetase                         391
  24          PFE1360c                     methionine aminopeptidase, putative                    386
  24          PF14_0327               methionine aminopeptidase, type II, putative                386
  24          PFF1155w                                 hexokinase                                 386
  24          PFI1110w         glutamate---ammonia ligase (glutamine synthetase), putative        386
  24          PFC0525c                     glycogen synthase kinase, putative                     386
  24          PF10_0150                    methionine aminopeptidase, putative                    386
  24          PFI1170c                            thioredoxin reductase                           386
  24          PF11_0164                    peptidyl-prolyl cis-trans isomerase                    386

Top targets for *P. falciparum* according to the search criteria shown in Query 4 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}.

Targets mentioned in the text are italicized.

10.1371/journal.pntd.0000804.t005

###### Application of standard search criteria to *M. tuberculosis*.
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  Ranking    Gene name                                                              Gene product                                                              Weight
  --------- ----------- ------------------------------------------------------------------------------------------------------------------------------------ --------
  *1*        *Rv1484*                   *nadh-dependent enoyl-\[acyl-carrier-protein\] reductase inha (nadh-dependent enoyl-acp reductase)*                   *511*
  *2*        *Rv2220*                                         *glutamine synthetase glna1 (glutamine synthase) (gs-i)*                                        *451*
  *3*        *Rv3227*        *3-phosphoshikimate 1-carboxyvinyltransferase aroa (5-enolpyruvylshikimate-3-phosphate synthase) (epsp synthase) (epsps)*        *426*
  4           Rv3581c                                probable 2c-methyl-d-erythritol 2,4-cyclodiphosphate synthase ispf (mecps)                                406
  4           Rv2763c                                   dihydrofolate reductase dfra (dhfr) (tetrahydrofolate dehydrogenase)                                   406
  4           Rv2537c                               3-dehydroquinate dehydratase arod (aroq) (3-dehydroquinase) (type ii dhqase)                               406
  4           Rv3602c                   probable pantoate---beta-alanine ligase panc (pantothenate synthetase) (pantoate activating enzyme)                    406
  4           Rv1293                                      probable diaminopimelate decarboxylase lysa (dap decarboxylase)                                      406
  9           Rv0533c                     3-oxoacyl-\[acyl-carrier-protein\] synthase iii fabh (beta-ketoacyl-acp synthase iii) (kas iii)                      401
  9           Rv2861c                                       probable methionine aminopeptidase mapb (map) (peptidase m)                                        401
  9           Rv2860c                                     probable glutamine synthetase glna4 (glutamine synthase) (gs-ii)                                     401
  9           Rv2222c                                     probable glutamine synthetase glna2 (glutamine synthase) (gs-ii)                                     401
  9           Rv1878                                      probable glutamine synthetase glna3 (glutamine synthase) (gs-i)                                      401
  14          Rv2870c     probable 1-deoxy-d-xylulose 5-phosphate reductoisomerase dxr (dxp reductoisomerase) (1-deoxyxylulose-5-phosphate reductoisomeras     396
  15          Rv3566c                                         arylamine n-acetyltransferase nat (arylamine acetylase)                                          391
  15          Rv1207                          probable dihydropteroate synthase 2 folp2 (dhps 2) (dihydropteroate pyrophosphorylase 2)                         391
  15          Rv2225                                       probable 3-methyl-2-oxobutanoate hydroxymethyltransferase panb                                      391
  15          Rv3628      inorganic pyrophosphatase ppa (pyrophosphate phospho-hydrolase) (ppase) (inorganic diphosphatase) (diphosphate phospho-hydrolase     391
  15          Rv3014c                          probable dna ligase \[nad dependent\] liga (polydeoxyribonucleotide synthase \[nad+\])                          391
  20          Rv1483     3-oxoacyl-\[acyl-carrier protein\] reductase fabg1 (3-ketoacyl-acyl carrier protein reductase) (mycolic acid biosynthesis a protei    386
  20          Rv1007c                                probable methionyl-trna synthetase mets (metrs) (methionine---trna ligase)                                386
  20          Rv0014c                             transmembrane serine/threonine-protein kinase b pknb (protein kinase b) (stpk b)                             386
  23          Rv2428                                   alkyl hydroperoxide reductase c protein ahpc (alkyl hydroperoxidase c)                                  381
  24          Rv0764c         cytochrome p450 51 cyp51 (cypl1) (p450-l1a1) (sterol 14-alpha demethylase) (lanosterol 14-alpha demethylase) (p450-14dm)         376

Top targets for *M. tuberculosis* according to the search criteria shown in Query 5 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}. Targets mentioned in the text are italicized.

*T. brucei* and *P. falciparum*: Metabolic Pathway- and Organelle-Specific Targets {#s3b}
----------------------------------------------------------------------------------

While TDRtargets.org integrates numerous datasets relevant to target prioritization, it cannot possibly anticipate every possible prioritization strategy that could be used by any given researcher. Accordingly, users can upload (weighted or unweighted) lists of targets meeting any criteria for which they have relevant data; these may then be combined with other queries covered by TDRtargets.org. Supplementation of standard TDRtargets.org criteria with a user-provided criterion is illustrated in the following example. Researchers specializing in the *T. brucei* glycolytic pathway are convinced that this pathway is essential in these parasites and wish to rank the enzymes within this pathway for their suitability as drug targets. Since they already assume the pathway to be essential and know glycolysis is also present in host cells, they may not address these issues in their search criteria, but may instead award points as listed in Query 6 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}. The query shown there combines criteria addressing integral TDRtargets.org data (such as availability of structural models) with a user-generated list of "bonus points" to some *T. brucei* enzymes in proportion to their relative control over the glycolytic flux [@pntd.0000804-Albert1]. The rationale for such a scoring might be that the greater an enzyme\'s flux control, the less completely it must be inhibited for flux through the entire pathway to be affected (and thus the better a target it is). In this example, the inclusion of flux control as a criterion lifts the two glycosomal orthologs of glyceraldehyde-3-phosphate dehydrogenase, the enzyme with the highest control coefficient, to the top of the priority list ([Table 6](#pntd-0000804-t006){ref-type="table"}). The recent genetic validation of this enzyme [@pntd.0000804-Caceres1] likewise identifies it as a possible target of interest. Interestingly, hexokinase was thought to have a much lower control coefficient [@pntd.0000804-Albert1] but may also have promise as a drug target [@pntd.0000804-Sharlow1].

10.1371/journal.pntd.0000804.t006

###### Prioritization of glycolytic enzymes in *T. brucei*.

![](pntd.0000804.t006){#pntd-0000804-t006-6}

  Ranking      Gene name                                             Gene product                                           Weight
  --------- ---------------- --------------------------------------------------------------------------------------------- --------
  1           Tb927.1.700                                       phosphoglycerate kinase                                      1101
  1           Tb11.02.3210                                     triosephosphate isomerase                                     1101
  *1*        *Tb927.6.4300*                     *glyceraldehyde 3-phosphate dehydrogenase, glycosomal*                      *1101*
  *1*        *Tb927.6.4280*                     *glyceraldehyde 3-phosphate dehydrogenase, glycosomal*                      *1101*
  5           Tb927.1.710                                       phosphoglycerate kinase                                      1081
  5          Tb09.211.0540                               fructose-1,6-bisphosphate, cytosolic                                1081
  *5*        *Tb10.70.5800*                                          *hexokinase*                                           *1081*
  *5*        *Tb10.70.5820*                                          *hexokinase*                                           *1081*
  9           Tb927.3.3270                    ATP-dependent phosphofructokinase,6-phospho-1-fructokinase                     1071
  9           Tb10.70.1370                            fructose-bisphosphate aldolase, glycosomal                             1071
  9           Tb927.1.3830                             glucose-6-phosphate isomerase, glycosomal                             1071
  9           Tb10.70.4740                                              enolase                                              1071
  13          Tb927.1.720                                       phosphoglycerate kinase                                      1061
  13         Tb10.6k15.3850                       glyceraldehyde 3-phosphate dehydrogenase, cytosolic                        1061
  15          Tb927.3.4390                             dihydrolipoamide dehydrogenase, putative                              1051
  15          Tb11.01.8100                                         enolase, putative                                         1051
  15          Tb10.61.2680                                         pyruvate kinase 1                                         1051
  15         Tb09.211.1370                        glyceraldehyde-3-phosphate dehydrogenase, putative                         1051
  15          Tb927.8.7380    dihydrolipoamide dehydrogenase, point mutation,acetoin dehydrogenase e3 component, putative    1051
  15          Tb927.4.5040                             dihydrolipoamide dehydrogenase, putative                              1051
  15          Tb927.5.3580                             phosphoglycerate mutase protein, putative                             1051
  15          Tb11.01.8470                                    dihydrolipoyl dehydrogenase                                    1051
  23         Tb10.6k15.2620                   2,3-bisphosphoglycerate-independent phosphoglycerate mutase                    1031
  23          Tb927.8.2520                                  acetyl-CoA synthetase, putative                                  1031
  25          Tb927.6.3050                              aldehyde dehydrogenase family, putative                              1011
  25         Tb10.6k15.3080                     dihydrolipoamide acetyltransferase precursor, putative                       1011
  25          Tb10.70.5380                           dihydrolipoamide acetyltransferase, putative                            1011
  25         Tb10.389.0890                    pyruvate dehydrogenase E1 component alpha subunit, putative                    1011
  25          Tb927.3.2030                                     acylphosphatase, putative                                     1011
  25          Tb927.6.4210                                 aldehyde dehydrogenase, putative                                  1011
  25          Tb927.3.1790                         pyruvate dehydrogenase E1 beta subunit, putative                          1011
  32          Tb10.70.2900          2-oxoisovalerate dehydrogenase beta subunit, mitochondrial precursor, putative           1001

Top targets according to the search criteria shown in Query 6 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}. Targets mentioned in the text are italicized.

The next scenario also employs a user-provided list, which in this case permits scrutiny of a specific organelle rather than a specific metabolic pathway. Consider a newly independent crystallographer with a special interest in *Plasmodium* apicoplasts, which are absent from the human host and thus are likely to contain many appealing drug targets [@pntd.0000804-Tonkin1]. The PlasmoAP algorithm [@pntd.0000804-Foth1] predicts that 485 proteins are localized to the apicoplast; the user can download this list from PlasmoDB.org [@pntd.0000804-Aurrecoechea1], manually delete proteins that seem unlikely to reside in the apicoplast, and then upload the modified list to TDRtargets.org. In sorting through the ∼400 proteins likely to reside in the apicoplast, the user may decide to minimize competition with labs already working on apicoplast biology by penalizing well-studied proteins (e.g., subtracting 100 points from targets whose 3D structures have already been solved) while rewarding other desirable characteristics such as those discussed above (likely essentiality, lack of orthologs in humans, etc.). Finally, a previous publication [@pntd.0000804-Mehlin1] has convinced the hypothetical user that a low molecular weight and low isoelectric point (pI) improve the odds of successful expression of soluble *Plasmodium* proteins, so those factors are weighted accordingly (Query 7 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}). The most highly ranked proteins in this example ([Table 7](#pntd-0000804-t007){ref-type="table"}) include some proteins (e.g., pseudouridine synthetase and cysteine desulfurase) that are rarely mentioned in the *Plasmodium* literature, consistent with this researcher\'s desire to explore truly novel target options.

10.1371/journal.pntd.0000804.t007

###### Possible novel drug targets in *P. falciparum* apicoplasts.

![](pntd.0000804.t007){#pntd-0000804-t007-7}

  Ranking     Gene name                          Gene product                         Weight
  --------- ------------- ---------------------------------------------------------- --------
  1           PF13_0176            apurinic/apyrimidinic endonuclease Apn1             1286
  2           PFA0225w                           LytB protein                          1276
  3          MAL13P1.221                aspartate carbamoyltransferase                 1261
  *3*        *PFB0890c*              *pseudouridine synthetase, putative*             *1261*
  *3*        *PF07_0068*               *cysteine desulfurase, putative*               *1261*
  3           PF10_0221                          GcpE protein                          1261
  7           PF14_0063              ATP-dependent Clp protease, putative              1256
  7           PF11_0270              threonine --- tRNA ligase, putative               1256
  9           PFI1240c                 prolyl-t-RNA synthase, putative                 1241
  9           PFL1120c                  DNA GyrAse a-subunit, putative                 1241
  9           PF10_0053                     tRNA ligase, putative                      1241
  12          PFL0770w                 seryl-tRNA synthetase, putative                 1236
  12          PF07_0129                 ATP-dept. acyl-coa synthetase                  1236
  12          PFE0475w              asparagine --- t RNA ligase, putative              1236
  12          PF10_0363                   pyruvate kinase, putative                    1236
  12          PF13_0354                alanine---tRNA ligase, putative                 1236
  12          PFB0695c                       acyl-CoA synthetase                       1236
  12          PFE0205w                 ATP-dependent helicase, putative                1236
  12          PF13_0077                  DEAD box helicase, putative                   1236
  20         MAL13P1.281              glutamate---tRNA ligase, putative                1231
  20          PF14_0348    ATP-dependent Clp protease proteolytic subunit, putative    1231
  22          PF14_0112                         POM1, putative                         1221
  23          PF11_0174                      hypothetical protein                      1216
  23          PF08_0108                      pepsinogen, putative                      1216
  23          PFL2395c             dimethyladenosine transferase, putative             1216
  23          PFE0195w                     P-type ATPase, putative                     1216

Top targets according to the search criteria shown in Query 7 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}. Proteins shown are likely to (A) be good drug targets, (B) be amenable to crystallization, and (C) reside in the apicoplast. Targets mentioned in the text are italicized.

*Trypanosoma cruzi*: Candidate Targets Associated with an Intracellular Lifestyle {#s3c}
---------------------------------------------------------------------------------

Unlike the bloodstream trypomastigotes of African Trypanosomes (Salivaria), the *T. cruzi* (Stercoraria) bloodstream forms do not replicate, and instead invade cells. In this parasitic strategy, which is shared with *Leishmania* spp., the replicative amastigotes are the intracellular parasite forms that persist and maintain the infection. Given the early evolutionary divergence of Salivarian trypanosomes [@pntd.0000804-Haag1] and the different strategies used by Salivarian and Stercorarian parasites to mount and maintain an infection, these groups of parasites may exhibit numerous instances of (A) gene loss and (B) gene duplications followed by neofunctionalization [@pntd.0000804-Lynch1]. Proteins that are orthologous between *T. cruzi* and *Leishmania* but that lack *T. brucei* counterparts may represent proteins vital to intracellular survival and/or growth, which could be excellent targets for drug development.

To look for such proteins, we used a general strategy similar to that used for *Leishmania* (see Query 3 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}) but now focused on *T. cruzi*, with an extra phylogeny-based restriction: additional weight was added to proteins that have been conserved in *Leishmania* and *T. cruzi* but that have been lost or substantially changed in *T. brucei.* The attributes and weights used in this query are shown in Query 8 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}. The strategy also relies on proteomic evidence of expression in intracellular amastigotes [@pntd.0000804-Atwood1]. However, because the proteomic data have a low coverage of the proteome, only a moderate weight has been assigned to this criterion. (This illustrates users\' ability to assign relative weights based not only on which characteristics they consider predictive of target desirability, but also on their confidence that available experimental datasets accurately reflect those characteristics.)

The results of this prioritization of *T. cruzi* targets are shown in [Table 8](#pntd-0000804-t008){ref-type="table"}. Because of the hybrid nature of the strain used to sequence the genome of *T. cruzi*, the list is somewhat redundant: most single copy genes appear twice in all genome databases. The top 32 targets include representatives of validated pathways -- ergosterol biosynthesis, as represented by sterol C-24 reductase, and glycolysis, as represented by glucokinase -- and other interesting alternatives for drug development. As suggested above, glycolysis is an essential pathway in trypanosomes, and the glycosome-localized glucokinase has attracted interest as a possible target since it was discovered in the sequenced *Leishmania* and *T. cruzi* genomes [@pntd.0000804-Caceres2]. On the other hand, the top- ranked sterol C-24 reductase provides a good example of the attractiveness of the phylogenetic criteria used in this strategy. The ergosterol biosynthesis pathway is also present in *T. brucei*, although it is not essential for the bloodstream forms, which scavenge sterols from the host [@pntd.0000804-Coppens1]. This highly ranked C-24 reductase belongs to the OrthoMCL ortholog group OG4_16908 (OrthoMCL version 4), which contains orthologs from the genomes of *T. cruzi, L. major*, and yeast (ERG4). However, this enzyme is apparently absent in the genomes of *T. brucei TREU927*, *T. brucei gambiense*, *T. vivax*, *and T. congolense.* In yeast, ERG4 catalyzes the final step in ergosterol biosynthesis, and although mutants are viable, they show a number of abnormal phenotypes and decreased fitness (see <http://www.yeastgenome.org/cgi-bin/locus.fpl?locus=ERG4>).

10.1371/journal.pntd.0000804.t008

###### Possible *T. cruzi* drug targets likely to be important in intracellular survival.

![](pntd.0000804.t008){#pntd-0000804-t008-8}

  Ranking           Gene name                                  Gene product                           Weight
  --------- -------------------------- ------------------------------------------------------------- --------
  1           Tc00.1047053508111.30                  glutamate dehydrogenase, putative                 466
  *1*        *Tc00.1047053510879.80*               *serine acetyltransferase, putative*               *466*
  *1*        *Tc00.1047053504013.40*               *serine acetyltransferase, putative*               *466*
  4           Tc00.1047053507875.20                  glutamate dehydrogenase, putative                 456
  *5*        *Tc00.1047053511277.600*                *hypothetical protein, conserved*                *436*
  *6*        *Tc00.1047053510187.100*                    *glucokinase 1, putative*                    *421*
  7           Tc00.1047053503745.30              ascorbate-dependent peroxidase, putative              416
  8           Tc00.1047053506193.60              ascorbate-dependent peroxidase, putative              406
  8           Tc00.1047053507993.160                  hypothetical protein, conserved                  406
  8            Tc00.1047053503749.5      pyrroline-5-carboxylate synthetase-like protein, putative     406
  8           Tc00.1047053508699.120                  dipeptidyl-peptidase, putative                   406
  8           Tc00.1047053509205.120                  hypothetical protein, conserved                  406
  *13*       *Tc00.1047053509073.70*    *phosphatidate cytidylyltransferase-like protein, putative*   *396*
  13          Tc00.1047053508601.141                  dipeptidyl-peptidase, putative                   396
  13          Tc00.1047053508707.140     phosphatidate cytidylyltransferase-like protein, putative     396
  *16*       *Tc00.1047053509287.20*                    *protein kinase, putative*                    *386*
  16          Tc00.1047053506577.60                   hypothetical protein, conserved                  386
  16          Tc00.1047053506953.30                      protein kinase, putative                      386
  *19*       *Tc00.1047053506839.60*         *tyrosine specific protein phosphatase, putative*        *381*
  19          Tc00.1047053506737.20                      protein kinase, putative                      381
  19          Tc00.1047053511277.210             peroxisomal enoyl-coa hydratase, putative             381
  19          Tc00.1047053508717.10           tyrosine specific protein phosphatase, putative          381
  19          Tc00.1047053508637.90                    phosphoglucomutase, putative                    381
  24          Tc00.1047053506725.20                   hypothetical protein, conserved                  376
  24          Tc00.1047053508461.80                   prostaglandin F2alpha synthase                   376
  *24*       *Tc00.1047053506577.120*                *sterol C-24 reductase, putative*                *376*
  24          Tc00.1047053511761.60                   hypothetical protein, conserved                  376
  24           Tc00.1047053507617.9                   prostaglandin F2alpha synthase                   376
  24          Tc00.1047053508955.20                   hypothetical protein, conserved                  376
  24          Tc00.1047053507089.170                  hypothetical protein, conserved                  376
  24          Tc00.1047053506679.130                  hypothetical protein, conserved                  376
  24          Tc00.1047053507709.60                   hypothetical protein, conserved                  376

Top targets according to the search criteria shown in Query 8 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}. Targets mentioned in the text are italicized.

Another top-ranking target in [Table 8](#pntd-0000804-t008){ref-type="table"} is the *T. cruzi* serine acetyltransferase (TcSAT), involved in the *de novo* synthesis of cysteine, which is present in *Leishmania* and *T. cruzi* and absent in *T. brucei* [@pntd.0000804-Williams1]. Cysteine in these parasites is important for the biosynthesis of polyamines and for antioxidant metabolism based on trypanothione, the trypanosome equivalent of glutathione. Inhibitors of the *E. coli* SAT enzyme have recently been shown to inhibit the growth of *Entamoeba histolytica,* another pathogen that is highly sensitive to oxidative stress [@pntd.0000804-Agarwal1].

Other interesting targets in this list include a putative amine oxidase (Tc00.1047053511277.600) which further analysis shows is conserved in several *Leishmania* species but absent in sequenced *T. brucei* subspecies; a putative phosphatidate cytidylyltransferase (Tc00.1047053509073.70) that belongs to an ortholog group with a very restricted phylogenetic distribution (OG4_29276), with members from many *Leishmania* species with complete genomes, *Entamoeba histolytica* (another pathogen), and two non-pathogenic species (*Thalassiosira pseudonana* and *Aquifex aeolicus*); a protein kinase (Tc00.1047053509287.20) whose yeast orthologs regulate endocytosis through the organization and function of the actin cytoskeleton; and a tyrosine protein phosphatase (Tc00.1047053506839.60) that also shows an unusual phylogenetic distribution, being almost exclusively present in *T. cruzi, Leishmania* spp., and metazoa.

*Mycobacterium tuberculosis*: Exploiting Previous Prioritizations {#s3d}
-----------------------------------------------------------------

Previous target prioritization efforts [@pntd.0000804-Anishetty1]--[@pntd.0000804-Raman1] raise the question of how these efforts should be viewed in relation to TDRtargets.org. We consider TDRtargets.org to be complementary to others\' prioritization work, and anticipate that it can be used to combine and apply the ranking methods of other target identification efforts. For instance, a recent paper on *M. tuberculosis* by Hasan and colleagues [@pntd.0000804-Hasan1] provided an excellent synthesis of experimental data to rank targets by persistence in dormant stages. These data (available in [@pntd.0000804-Hasan1] as Supplemental Dataset S1, and also at <http://tdrtargets.org/published/browse/379>) can be easily interrogated and combined with other queries using TDRtargets.org. For example, while Hasan *et al.*\'s rankings considered proteins essential for growth on defined medium *in vitro* [@pntd.0000804-Lamichhane1], [@pntd.0000804-Sassetti1], they did not reward proteins thought to be essential for growth in macrophages or in the infection of mice [@pntd.0000804-Sassetti2], [@pntd.0000804-Rengarajan1], which may well be very relevant to human infection. In addition, because Hasan *et al.* awarded points to proteins with solved crystal structures, it seems apt to give points to proteins whose structures have been solved during the four years that have elapsed since the original analysis was published. TDRtargets.org was therefore used to make a few modifications to one set of Hasan *et al.* \'s rankings: the set that emphasized targets\' likely importance in persistent-stage disease. We uploaded a modified version of this list that excluded points for PDB structures, then gave additional points to all genes represented in the Protein Data Bank of crystal structures [@pntd.0000804-Kouranov1] as of April 2010. To these subtotals, we added points based on an analysis of latent-stage infections by Murphy & Brown [@pntd.0000804-Murphy1]. In that analysis, genes were given upregulation and downregulation scores based on their expression in various models of dormancy, thus offering a distinct estimate of genes\' importance during latency, and "attenuation" scores based on the effect of gene knockouts on growth in various contexts, including the macrophage and mouse studies noted above. (See "Additional file 1" from [@pntd.0000804-Murphy1]; see also <http://tdrtargets.org/published/browse/383>.) The combined input of the two previous studies was thus used to create a "consensus list" ([Table 9](#pntd-0000804-t009){ref-type="table"}) that might be considered superior to either one alone. Combining the two previous analyses could also be done off-line using spreadsheets, but performing these operations within TDRtargets.org is considerably faster and facilitates retrieval of TDRtargets.org-compiled information on each individual target. Naturally, our "consensus list" reflects the limitations of the previous analyses, e.g., the low rankings of important persistent-stage proteins such as Rv0470c (mycolic acid synthase, PcaA) and Rv2583c (GTP pyrophosphokinase, RelA), as discussed by Hasan et al. [@pntd.0000804-Hasan1].

10.1371/journal.pntd.0000804.t009

###### Leading persistent-stage *M. tuberculosis* targets.

![](pntd.0000804.t009){#pntd-0000804-t009-9}

  Ranking    Gene name                                                             Gene product                                                             Weight
  --------- ----------- ---------------------------------------------------------------------------------------------------------------------------------- --------
  1           Rv0885                                                      conserved hypothetical protein                                                     762
  2           Rv3290c                 probable l-lysine-epsilon aminotransferase lat (l-lysine aminotransferase) (lysine 6-aminotransferase)                 752
  3           Rv2004c                                                     conserved hypothetical protein                                                     717
  4           Rv2780                                       secreted l-alanine dehydrogenase ald (40 kda antigen) (tb43)                                      714
  5           Rv2628                                                           hypothetical protein                                                          679
  6           Rv2626c                                                     conserved hypothetical protein                                                     657
  6           Rv2623                                                  conserved hypothetical protein tb31.7                                                  657
  8           Rv3340     probable o-acetylhomoserine sulfhydrylase metc (homocysteine synthase) (o-acetylhomoserine (thiol)-lyase) (oah sulfhydrylase) (o    631
  9           Rv2497c    probable pyruvate dehydrogenase e1 component (alpha subunit) pdha (pyruvate decarboxylase) (pyruvate dehydrogenase) (pyruvic deh    615
  10          Rv2629                                                      conserved hypothetical protein                                                     613
  11          Rv2627c                                                     conserved hypothetical protein                                                     610
  12          Rv3130c                                                     conserved hypothetical protein                                                     605
  13          Rv2035                                                      conserved hypothetical protein                                                     602
  14          Rv2624c                                                     conserved hypothetical protein                                                     601
  15          Rv0678                                                      conserved hypothetical protein                                                     599
  16          Rv2032                                                    conserved hypothetical protein acg                                                   596
  17          Rv1813c                                                     conserved hypothetical protein                                                     594
  18          Rv3131                                                      conserved hypothetical protein                                                     591
  19          Rv2630                                                           hypothetical protein                                                          580
  20          Rv0251c                                heat shock protein hsp (heat-stress-induced ribosome-binding protein a)                                 579
  21          Rv1285                                           probable sulfate adenylyltransferase subunit 2 cysd                                           576
  22          Rv2830c                                                     conserved hypothetical protein                                                     569
  23          Rv0275c                                   possible transcriptional regulatory protein (possibly tetr-family)                                   566
  24          Rv2711                                               iron-dependent repressor and activator ider                                               565
  25          Rv3126c                                                          hypothetical protein                                                          556

Top targets according to the search criteria shown in Query 9 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}. In essence, previous analyses by Hasan et al. [@pntd.0000804-Hasan1] and Murphy & Brown [@pntd.0000804-Murphy1] were combined.

Helminths: The Importance of Homology {#s3e}
-------------------------------------

Since many valuable helminth datasets are only starting to emerge, our attempts to prioritize helminth targets required some analysis beyond the standard TDRtargets.org queries. For example, *B. malayi* and *S. mansoni* proteins are not yet scored for druggability in TDRtargets.org, so we assessed their druggability by comparing their amino acid sequences to those of known drug targets in the StARLITe/ChEMBL database [@pntd.0000804-Overington1]. The sequence similarity analysis was performed using BLAST; a helminth protein was considered druggable if (A) it is ≥80% of the length of the corresponding druggable target, (B) it has an amino-acid sequence that aligns with ≥80% of the druggable target, and (C) the BLAST expectation value of the alignment is less than 10^−10^ (database size: 11,508 genes for *B. malayi*, 13,331 genes for *S. mansoni*). In addition, proteins\' functional importance in helminths was inferred from knockout data taken from their orthologs in *C. elegans* and *D. melanogaster* (see [Materials and Methods](#s2){ref-type="sec"} and Queries 10 and 11 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}). Being able to connect the helminth proteins to similar proteins in other species was thus critical in allowing us to evaluate their potential as drug targets.

Our strategy of relying heavily on orthology and sequence similarity to rank helminth targets is broadly similar to those used by Kumar *et al.* [@pntd.0000804-Kumar1] to rank *Brugia* targets and by Caffrey *et al.* [@pntd.0000804-Caffrey1] to rank *Schistosoma* targets. However, these authors sought targets that met each of several desired criteria (Boolean "AND"); for example, Kumar *et al.* only considered *Brugia* proteins with orthologs in *C. elegans* but not in humans, and whose absence causes deleterious phenotypes (according to RNAi of *C. elegans* orthologs). In contrast, we again used the "weighted union" approach to avoid premature elimination of any proteins from consideration as targets. Kumar *et al.* also took a distinct approach to druggability, rewarding proteins with domains targeted by compounds obeying the Lipinski "Rule of 5" [@pntd.0000804-Hopkins1] and having EC numbers associated with druggability. Additionally, Kumar *et al.* penalized proteins for hydropathicity (which reduces the ease of recombinant expression) and rewarded them for being expressed (according to a small dataset of expressed sequence tags, or ESTs, encompassing 250 genes); in contrast, we gave additional points to all proteins having EC numbers (and therefore presumed to be enzymes), 3D structural models, and/or bibliographic references.

A comparison of our helminth prioritizations ([Tables 10](#pntd-0000804-t010){ref-type="table"} and [11](#pntd-0000804-t011){ref-type="table"}) with those of Kumar *et al.* [@pntd.0000804-Kumar1] and Caffrey *et al.* [@pntd.0000804-Caffrey1] reveals relatively little concordance. Among our top 200 *Brugia* targets, none are also among the top 200 as ranked by Kumar *et al*. (see Supplementary Table S1 of [@pntd.0000804-Kumar1], also available at <http://tdrtargets.org/published/browse/282>). This lack of overlap is likely due in part to (A) our emphasis on druggability, as inferred from sequence similarity against targets in the ChEMBL database, and (B) the fact that we didn\'t penalize proteins with human orthologs (see [Discussion](#s4){ref-type="sec"} subsection "No List is Canonical"). By adding two conditions to the weighted union to penalize proteins with orthologs in human and in mouse (with weights −40 and −20, respectively), some overlap between both lists can be observed: among our top 200 targets, 32 are also among the top 200 as ranked by Kumar *et al*. One unique aspect of our list is that it includes four tRNA synthetases among the top 39 proteins. These enzymes have been proposed as drug targets in *Brugia*, and are also considered good drug target candidates in other parasites such as trypanosomes [@pntd.0000804-Merritt1], since they must be essential but often have major structural differences with respect to the human orthologs.

10.1371/journal.pntd.0000804.t010

###### Rankings of possible *Brugia malayi* drug targets.

![](pntd.0000804.t010){#pntd-0000804-t010-10}

  Ranking     Gene name                                        Gene product                                        Weight
  --------- ------------- --------------------------------------------------------------------------------------- --------
  1           Bm1_35945                          Protein kinase domain containing protein                           190
  *2*        *Bm1_25205*                            *leucyl-tRNA synthetase, putative*                             *188*
  2           Bm1_46445                               vacuolar proton pump, putative                                188
  2           Bm1_31340                               vacuolar proton pump, putative                                188
  5           Bm1_38680                            tubulin alpha chain - mouse, putative                            178
  5           Bm1_20715                               tubulin alpha-2 chain, putative                               178
  5           Bm1_25035                               Tubulin alpha-2 chain, putative                               178
  5           Bm1_30720                                     KE2 family protein                                      178
  5           Bm1_39900                           Sex muscle abnormal protein 5, putative                           178
  *5*        *Bm1_32860*                             *Valyl-tRNA synthetase, putative*                             *178*
  5           Bm1_14145                    protein phosphatase PP2A regulatory subunit, putative                    178
  5           Bm1_44205                        V-type ATPase 116 kDa subunit family protein                         178
  5           Bm1_48675                  GTP-binding regulatory protein Gs alpha-S chain, putative                  178
  5           Bm1_28835    Transcription initiation factor IIA, gamma subunit, helical domain containing protein    178
  5           Bm1_55400                               Tubulin alpha-2 chain, putative                               178
  5           Bm1_46210                          Protein kinase domain containing protein                           178
  5           Bm1_43680                        T-complex protein 1, alpha subunit, putative                         178
  5           Bm1_30260                                Tubulin alpha chain, putative                                178
  5           Bm1_44630             oxidoreductase, short chain dehydrogenase/reductase family protein              178
  20          Bm1_10280                                   transketolase, putative                                   173
  21          Bm1_20815                              integrin-linked kinase, putative                               170
  21          Bm1_54155                      Probable dimethyladenosine transferase, putative                       170
  23          Bm1_19675           Serine/threonine protein phosphatase F56C9.1 in chromosomeIII, putative           168
  23          Bm1_50960           vacuolar ATP synthase catalytic subunit A, osteoclast isoform, putative           168
  23          Bm1_52850                    mannose-6-phosphate isomerase, class I family protein                    168
  *23*       *Bm1_12165*                           *methionyl-tRNA synthetase, putative*                           *168*
  23          Bm1_48165                              Adenosylhomocysteinase, putative                               168
  23          Bm1_32455                    mannose-6-phosphate isomerase, class I family protein                    168
  23          Bm1_22825              Protein prenyltransferase alpha subunit repeat containing protein              168
  23          Bm1_14125                          proteasome subunit beta type 1, putative                           168
  23          Bm1_17330    succinate dehydrogenase \[ubiquinone\] flavoprotein subunit, mitochondrial, putative     168
  23          Bm1_45960                 ATP synthase beta chain, mitochondrial precursor, putative                  168
  23          Bm1_12875          Serine/threonine protein phosphatase PP1-beta catalytic subunit, putative          168
  *23*       *Bm1_41830*                            *Alanyl-tRNA synthetase, putative*                             *168*
  23          Bm1_38390                              protein phosphatase 2A., putative                              168
  23          Bm1_24805                          proteasome subunit beta type 3, putative                           168
  23          Bm1_41940                     Glyceraldehyde 3-phosphate dehydrogenase, putative                      168
  23          Bm1_41510                            FAD binding domain containing protein                            168
  23          Bm1_51640                         Proteasome A-type and B-type family protein                         168

Top targets according to the search criteria shown in Query 10 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}. Targets mentioned in the text are italicized.

10.1371/journal.pntd.0000804.t011

###### Rankings of possible *Schistosoma mansoni* drug targets.

![](pntd.0000804.t011){#pntd-0000804-t011-11}

  Ranking      Gene name                                                       Gene product                                                     Weight
  --------- ---------------- ----------------------------------------------------------------------------------------------------------------- --------
  *1*         *Smp_015020*                                        *na+/k+ atpase alpha subunit, putative*                                       *120*
  2           Smp_059790.2                                                transketolase, putative                                                119
  2           Smp_059790.1                                                transketolase, putative                                                119
  4            Smp_040790                                                 cyclophilin B, putative                                                113
  5           Smp_040970.1                                           vacuolar proton atpases, putative                                           112
  *5*         *Smp_027920*                                            *tubulin alpha chain, putative*                                           *112*
  *7*         *Smp_016780*                                            *tubulin alpha chain, putative*                                           *109*
  *8*         *Smp_103140*                                               *alpha-tubulin, putative*                                              *106*
  8            Smp_029390                                      ATP synthase subunit beta vacuolar, putative                                      106
  10           Smp_106150                                   carbamoyl-phosphate synthase large chain, putative                                   103
  *10*        *Smp_142050*                                                  *erk1/2, putative*                                                  *103*
  10           Smp_071840                                       6-phosphogluconate dehydrogenase, putative                                       103
  *10*        *Smp_030730*                                            *tubulin beta chain, putative*                                            *103*
  14          Smp_059340.1    Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein), putative    102
  *14*       *Smp_090120.2*                                              *alpha tubulin, putative*                                              *102*
  *14*       *Smp_090120.1*                                              *alpha tubulin, putative*                                              *102*
  14          Smp_059340.2    Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein), putative    102
  14          Smp_043670.1                       6-phosphofructokinase (Phosphofructokinase) (Phosphohexokinase), putative                       102
  *14*        *Smp_155270*                                    *hydroxymethylglutaryl-CoA synthase, putative*                                    *102*
  *20*        *Smp_079960*                                            *tubulin beta chain, putative*                                            *100*
  *20*        *Smp_035760*                                            *tubulin beta chain, putative*                                            *100*
  *20*        *Smp_078040*                                            *tubulin beta chain, putative*                                            *100*
  *20*        *Smp_079970*                                            *tubulin beta chain, putative*                                            *100*
  24           Smp_165490                                            protein phsophatase-2a, putative                                             99
  24           Smp_097590                                             valyl-tRNA synthetase, putative                                             99
  24          Smp_096020.2                                           adenosylhomocysteinase, putative                                             99
  24          Smp_096020.1                                           adenosylhomocysteinase, putative                                             99
  24          Smp_028990.1                                            protein phosphatase-1, putative                                             99
  24          Smp_096020.3                                           adenosylhomocysteinase, putative                                             99
  24          Smp_028440.1                                           adenosylhomocysteinase, putative                                             99
  24          Smp_028440.3                                           adenosylhomocysteinase, putative                                             99
  24           Smp_034490                                       proteasome subunit beta type 6,9, putative                                        99
  24           Smp_138590                                               hmg-CoA reductase, putative                                               99

Top targets according to the search criteria shown in Query 11 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}. Targets mentioned in the text are italicized.

The list of 57 recommended *Schistosoma* targets generated by Caffrey and colleagues (see Table S1 of [@pntd.0000804-Caffrey1], also available at <http://tdrtargets.org/published/browse/247>) includes 18 targets they considered to be of the highest priority because they are druggable, are expressed in relevant life-cycle stages, yield deleterious phenotypes, and are homologous to proteins with solved crystal structures including co-crystallized ligands. Of these 18 targets, eight rank within our 170 top *Schistosoma* targets. An obvious difference between the two lists is that ours includes nine tubulins among the top 23 proteins. The prominence of the tubulins is consistent with beta-tubulin\'s validation as a helminth drug target [@pntd.0000804-Robinson1]. A number of ATPases also appear among our top targets. The top-ranked target in our list is the alpha (catalytic) subunit of a Na^+^/K^+^ ATPase (Smp_015020), which in mammals (and probably also in schistosomes) is the target of ouabain and other cardiac glycosides [@pntd.0000804-Fetterer1]. This target does not appear in the list of 57 targets published by Caffrey *et al.*; however, the beta subunit of this or a closely related Na^+^/K^+^ ATPase (Smp_124240) is ranked \#52 in this study. Other attractive targets include a putative extracellular-signal-regulated kinase (ERK, Smp_142050), and a putative HMG-CoA reductase (Smp_138590), which is the target of cholesterol-lowering drugs like mevinolin [@pntd.0000804-Vandewaa1].

Discussion {#s4}
==========

Stability of Ranked Lists {#s4a}
-------------------------

A relevant question for any ranked list of targets using any strategy is: how different would this list be if the weight given to a certain attribute is changed? Using the *M. tuberculosis* queries whose results are in [Table 5](#pntd-0000804-t005){ref-type="table"}, we analyzed the robustness of the final ranked list, by selecting one attribute at a time and changing its weight from a very low (negative) score to a very high (positive) score. To assess the change observed in the ranked list we counted the number of curated targets (i.e., those with some level of validation) observed within the top 200 targets in the ranked list and used this value as our objective function (see panel B in [Figure 3](#pntd-0000804-g003){ref-type="fig"}). Using this measure, we observed that a high score is obviously needed for those attributes that are enriched in validated targets (see panel A in [Figure 3](#pntd-0000804-g003){ref-type="fig"}) in order to find well-known targets at the top of the list. This is also true for attributes that are not independent of these "good" attributes (e.g., availability of 3D structures). In contrast, changing the weight of attributes that are not expected to be enriched in validated drug targets (e.g., low molecular weight) does not affect the final result. In these cases, the final lists are all different, but they are consistent in having the highest ranks of the list being enriched in validated targets. In general, of course, targets\' rankings within a list can be increasingly stabilized by including more and more relevant criteria in the prioritization.

![The sensitivity of target rankings to changes in weighting.\
Using the *M. tuberculosis* genome as an example, we determined the fraction of genes matching an attribute/query in a set of curated targets (validated chemically and/or genetically) and in the entire genome. (A) The results are shown for each attribute used in Query 5 of [Figure 2](#pntd-0000804-g002){ref-type="fig"}. Values are log(Observed/Expected), where Expected is the fraction of genes in the genome that have the attribute and Observed is the fraction of curated targets that have the attribute. (B) We analyzed the stability of the final ranked list when the weight of a single attribute is changed. As an indication of stability, we plot the percentage of curated targets among the top 200 genes as the weight of each attribute is changed from minus-100 to plus-200.](pntd.0000804.g003){#pntd-0000804-g003}

Old Targets Versus New Targets {#s4b}
------------------------------

In analyzing target candidates, we often wonder what sort of mix of well-studied and not-so-well-studied proteins might be most "desirable" at the top of a ranked list. On the one hand, having well-known targets or targets of known drugs at the top of our lists offers some assurance that our search strategies are reasonable (i.e., they serve as "positive controls" of the strategy). On the other hand, a method that only identifies well-established targets would not serve the important purpose of suggesting novel targets, so the presence of novel (even "hypothetical") targets near the top of a list is also welcome. With the deliberate exception of [Table 7](#pntd-0000804-t007){ref-type="table"}, our lists reflect a desire to spotlight both previously validated and newly emerging targets.

In addition to trying to achieve a mix of new and established targets in prioritization lists, users need also to robustly consider which established targets they should classify as "successful." Some targets enjoy long-held high esteem within the research community in the absence of any clinical validation, while other proteins, particularly for the organisms being studied here, are targets of clinically used drugs whose product profiles are unlikely to be acceptable in future drug development programs.

False Negatives {#s4c}
---------------

Previous bioinformatic analyses of drug targets [@pntd.0000804-Hasan1] have suggested that certain established targets never rank highly unless given artificial boosts in points for that specific purpose. Examples of these "false negatives" are also apparent in the lists presented here. For instance, cytochrome b is the known target of the antimalarial drug atovaquone [@pntd.0000804-Mather1], yet it ranks in the bottom 25% of targets represented by [Table 4](#pntd-0000804-t004){ref-type="table"} because it has transmembrane domains (making recombinant expression difficult), is not easy to assay in isolation, lacks a known crystal structure, and so on. Likewise, certain targets of antihelminth drugs -- such as the acetylcholine and GABA receptors, glutamate-gated chloride channel, and SLO-1 potassium channel [@pntd.0000804-Martin1], [@pntd.0000804-HoldenDye1] -- do not appear near the top of our helminth lists. There are several possible (non-exclusive) explanations for this. First, some drugs were found through phenotypic screens and their targets do not meet many of the criteria required in a target-based approach, and thus might not be expected to rank highly. Second, current target prioritization strategies are generally based on the assumption that drugs will cause a loss-of-function phenotype, but most existing helminth drugs lead to gain-of-function phenotypes [@pntd.0000804-Martin1]. Ranking proteins according to their potential as gain-of-function targets might be a fruitful direction of future work. Finally, it is conceivable that the total number of viable drug targets vastly exceeds the number that have been clinically validated, such that the position of many non-validated targets ahead of some validated ones is appropriate.

False Positives {#s4d}
---------------

The failure of some validated targets to be highly ranked in our lists is not particularly surprising or troublesome, as discussed above. A more interesting issue is that of "false positives," i.e., proteins that do rank highly but have not been validated as drug targets despite considerable effort. For instance, the *Leishmania* adenosine kinase ranks among the top 25 proteins in [Tables 2](#pntd-0000804-t002){ref-type="table"} and [3](#pntd-0000804-t003){ref-type="table"}, yet turns out to be nonessential in promastigotes [@pntd.0000804-Hwang1]. Similarly, the *Plasmodium* enoyl-ACP reductase (FabI) ranks 2^nd^ in [Table 4](#pntd-0000804-t004){ref-type="table"}, yet is nonessential for blood-stage growth [@pntd.0000804-Vaughan1]. Among *M. tuberculosis* proteins, pantothenate kinase (PanK or CoaA) is in the top 100 of the Query 5 rankings (though not among the top 24 and thus not shown in [Table 5](#pntd-0000804-t005){ref-type="table"}), yet screens targeting this enzyme yielded no leads active against wild-type *M. tuberculosis* cells (C. E. Barry, personal communication). PanK activity *in vivo* appears to be so far in excess of what is required for growth that killing *M. tuberculosis* cells by inhibiting this enzyme is virtually impossible.

Although such examples can be seen as discouraging, we can use them to ask whether the incidence of false positives can be reduced through the use of additional datasets and search strategies. The nonessesentiality of the *Plasmodium* FabI during erythrocyte stages is perhaps suggested by the fact that expression of the enzyme is neither high nor tightly regulated during the erythrocyte life-cycle stages [@pntd.0000804-LeRoch1]. While TDRtargets.org does not currently offer a metric for the periodicity of gene expression in blood-stage *Plasmodium*, this could be added to future versions of the database.

No List Is Canonical {#s4e}
--------------------

The target rankings presented here are meant to be illustrative rather than definitive. The lists presented here were sent to experts on relevant neglected diseases for evaluation, and, predictably, we encountered numerous reasonable differences of opinion. For helminths, arguments were made both for and against penalizing proteins with orthologs in humans. The presence of human orthologs suggests an increased likelihood of toxicity in the host; on the other hand, several existing drug targets do have human orthologs. For *M. tuberculosis*, it was noted that existing drugs tend to target information-processing enzymes (DNA and RNA polymerase, DNA gyrase) rather than metabolic enzymes, so searches for new drugs might pay special attention to that area. Generally applicable suggestions included penalties for proteins that are part of macromolecular complexes, since they are hard to study in isolation, and for proteins of unknown function, since they are hard to study with biochemical or biophysical methods.

In addition to legitimate differences of opinion among researchers, the relative appeal of individual targets will continue to change as additional data are gathered. Fortunately, the infrastructure of TDRtargets.org is flexible enough to accommodate different individuals\' interests (as seen especially in the lists focused on *T. brucei* glycolysis and *Plasmodium* apicoplasts) and the incorporation of new data (most prominent in the rankings for the helminths and for *M. tuberculosis* persistence). We therefore see TDRtargets.org as a tool that individual scientists may use to explore new research directions, rather than as a final arbiter of proteins\' potential as drug targets.

As noted, target prioritization with TDRtargets.org or any other computational method is probably most useful as a prelude to (rather than a replacement of) laborious experimental follow-up work. Experimental characterization of promising targets often requires chemical inhibitors of target activity; therefore lists of target-specific inhibitors would be of great value to the research community. Though TDRtargets.org currently includes a preliminary dataset of such inhibitor-target associations, future editions of the database should offer major expansions and refinements of this dataset.
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